Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings Results

Corvus Pharmaceuticals (NASDAQ:CRVS) issued its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Trading Down 7.5 %

NASDAQ:CRVS opened at $3.93 on Wednesday. The stock has a market capitalization of $252.53 million, a P/E ratio of -4.23 and a beta of 0.91. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The firm has a 50 day moving average of $4.70 and a 200-day moving average of $6.09.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.